Ascendis Pharma AS (ASND - Free Report) shares soared 6.5% in the last trading session to close at $115.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22.5% loss over the past four weeks.
Earlier this month, the company announced that the European Commission has granted marketing authorization to TransCon hGH for the treatment of growth hormone deficiency in children and adolescents aged between three to 18 years. This might have driven the share price rally.
This company is expected to post quarterly loss of $2.58 per share in its upcoming report, which represents a year-over-year change of +18.1%. Revenues are expected to be $4.14 million, up 547.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ascendis Pharma AS, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ASND going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Ascendis Pharma AS (ASND - Free Report) shares soared 6.5% in the last trading session to close at $115.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22.5% loss over the past four weeks.
Earlier this month, the company announced that the European Commission has granted marketing authorization to TransCon hGH for the treatment of growth hormone deficiency in children and adolescents aged between three to 18 years. This might have driven the share price rally.
This company is expected to post quarterly loss of $2.58 per share in its upcoming report, which represents a year-over-year change of +18.1%. Revenues are expected to be $4.14 million, up 547.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ascendis Pharma AS, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ASND going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Get the latest research report on ASND - FREE